Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2022-06-07 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
德勤华永会计师事务所（特殊普通合伙）关于海创药业股份有限公司以自筹资金预先投入募集资金投资项目及支付发行费用情况的审核报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report related to the use of self-raised funds for investment projects and payment of issuance expenses, with detailed financial figures and references to an audit by Deloitte Huayong CPA firm. It includes specific financial data on funds raised, pre-investment amounts, and replacement arrangements, indicating it is a standalone audit or verification report rather than a full annual or interim report. The document length is 2687 characters, which is relatively short but contains substantive financial data and audit confirmation. It does not appear to be an announcement or a brief notice but a specialized audit report on fundraising and fund usage compliance. Therefore, the most appropriate classification is Audit Report / Information (AR). Q2 2022
2022-06-07 Chinese
第一届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company 海创药业股份有限公司 regarding several proposals related to the use and adjustment of raised funds, and the reappointment of the financial and internal control audit institution for 2022. It includes voting results and references other announcements published on the Shanghai Stock Exchange website. The document is short (1046 characters) and primarily reports on meeting decisions and resolutions rather than providing detailed financial data or full reports. It does not contain financial statements or detailed audit reports itself, nor is it a call transcript or management report. It is not an announcement of voting results from a shareholder meeting but from the Supervisory Board. The content fits best with a Regulatory Filing (RNS) as it is a formal regulatory announcement of board resolutions and related decisions without substantive financial data or full report content.
2022-06-07 Chinese
独立董事关于公司第一届董事会第二十三次会议相关事项的事前认可意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors providing their prior approval opinion regarding the reappointment of the company's financial and internal control audit firm for the year 2022. It references compliance with laws and regulations, the qualifications of the audit firm, and the audit report's objectivity. The document is short (924 characters) and does not contain actual financial statements or detailed audit results, but rather an opinion related to audit matters. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related information, excluding full annual reports. Therefore, the document is best classified as AR. FY 2022
2022-06-07 Chinese
中信证券股份有限公司关于海创药业股份有限公司使用募集资金置换预先投入募集资金投资项目及已支付发行费用的自筹资金的核査意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of raised funds by Haichuang Pharmaceutical Co., Ltd. to replace self-raised funds previously invested in projects and paid issuance expenses. It references regulatory approvals, specific fund amounts, audit reports, and board meeting approvals related to the use of IPO proceeds. The document is a formal verification and compliance opinion by the sponsor institution, including audit and board resolutions, but it is not a full annual or interim financial report, nor an earnings release or investor presentation. It is a specialized report related to the use and management of raised funds, which fits the category of Capital/Financing Update (CAP) as it deals with fundraising proceeds usage and related financial compliance matters. The document length is 3506 characters, which is substantive and contains detailed financial and procedural information, not just an announcement or certification. Therefore, the best classification is CAP with high confidence.
2022-06-07 Chinese
关于使用募集资金置换预先投入募集资金投资项目及已支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of raised funds to replace previously invested self-raised funds in investment projects and paid issuance expenses. It includes details about the fundraising, investment projects, replacement amounts, and opinions from independent directors, the supervisory board, accountants, and the sponsoring institution. The document is relatively short (4165 characters) and primarily serves as a formal disclosure of a financing-related transaction rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. The content aligns with updates on company fundraising and capital structure changes, which fits the Capital/Financing Update category. Therefore, the appropriate classification is CAP (Capital/Financing Update).
2022-06-07 Chinese
第一届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of the company 海创药业股份有限公司. It details the meeting date, attendance, agenda items, voting results, and references to related announcements on the stock exchange website. The content focuses on board decisions regarding fundraising investment adjustments, use of funds, and audit firm reappointment. There is no detailed financial data or comprehensive report content, but rather a summary of board meeting decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document length is short (1390 characters), and it is not a full report or financial statement. Therefore, the correct classification is MANG with high confidence.
2022-06-07 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.